Drug intelligence / Profile preview

HUBPE001.1

Development stage: Preclinical
Lead developer: Ambiotech
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Subcutaneous

Overview

HUBPE001.1 is an exosome-based therapy developed by AM Biotech using its proprietary Biochemical Pulse Exosome Drug Development Platform. Currently in preclinical development, the therapy is being investigated for a broad range of indications, including premature ovarian failure, menopausal symptoms, macular degeneration, and chronic renal failure. HUBPE001.1 leverages the regenerative and signaling properties of extracellular vesicles (exosomes) to deliver bioactive molecules to damaged or dysfunctional tissues, aiming to restore physiological function and promote tissue repair across multiple organ systems.

Beyond the preview

Go deeper on HUBPE001.1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HUBPE001.1.

Explore the full profile